Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
May 15, 2013 -- The Almac biocatalysis group has secured a prestigious BBSRC (Biotechnology and Biological Sciences Research Council) programme with UCL focused specifically on metagenomics and novel enzyme discovery. The R&D work concerned is set to be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, with high level input from two world leaders in the field of biocatalyst discovery and application, Professors John Ward and Helen Hailes.
Dr. Tom Moody, Almac’s Head of Biocatalysis & Isotope Chemistry, commented “This clearly adds further depth to our expertise and complements our recent collaboration with DSM in accessing diverse enzyme collections.”
Professor Ward remarked: “We are very excited to continue working with Almac on this prestigious project, building on many years of collaboration and partnership. Indeed, this project will see our internal capabilities further developed with true industrial needs in our vision.”
The application of biocatalysis technology to the pharmaceutical and fine chemical industries is continuing to grow year on year and this trend is mirrored in the increasing number of synthetic projects being carried out by the biocatalysis group in Almac.
The only limitation of biocatalysis is in the number of diverse enzymes available in a given enzyme class, which dictates both the substrate range and the stereoselectivity observed for a desired chemical transformation. The majority of enzymes used in biocatalysis are derived from microbial sources. However, it is known that only a tiny percentage (as low as 0.1% from soil samples) of bacteria present in an environmental sample can be cultured and isolated.
Metagenomics, a culture-independent technique used to extract the total DNA from an environment, can circumvent this problem and allow access up to 99% of enzyme genes present in environmental samples. Work previously carried out at UCL has allowed a series of metagenomes to be obtained from various unusual sources. The use of bioinformatic tools developed by John Ward with Prof Christine Orengo of the Structural and Molecular Biology department at UCL will allow the metagenomes concerned to be mined for enzymes usable in both synthetic chemistry and synthetic biology projects.
Moody further commented “The need for more diverse enzymes has never been greater and this research programme further emphasises Almac’s commitment to UK research and to biocatalysis development.”
He continued; “The project will mainly focus on transaminase and cytochrome P450s enzymes. We will identify, clone and express these enzymes before carrying out extensive screening against panels of ‘typical’ pharmaceutical and fine chemical substrates. This should enable us to identify novel and commercially useful enzyme biocatalysts. As the follow-on step, directed evolution at Almac will enable further development of the lead enzymes concerned.
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3938 or e-mail: email@example.com.
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
Help employers find you! Check out all the jobs and post your resume.